cbdMD, Inc. (NYSE: YCBD) reported Q3 EPS of $0.02, $0.06 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $10.6 million versus the consensus estimate of $13.4 million.

“We continue to build upon our success and develop our science and infrastructure, which we believe will drive shareholder value and separate our brands from our competition. We believe that our proven ability to innovate our marketing as well as deliver award winning products to our consumers will achieve significant and lasting market brand recognition and consumer acceptance for our cbdMD, Paw CBD and cbdMD Botanicals brands,” said Martin Sumichrast, Chairman and Co-CEO of cbdMD, Inc.

For earnings history and earnings-related data on cbdMD, Inc. (YCBD) click here.